Search research articles
Contact Us
Filters
Showing results (261-270 of 315) with videos related to
Page
of 32
Sort By:
Cardiology in the Young
|
February 12, 2011
Report from The International Society for Nomenclature of Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric cardiac disease (Part 1 - Procedural nomenclature)
Lisa Bergersen, Allen Dale Everett, Jorge Manuel Giroud, et al.
Circulation. Heart Failure
|
September 14, 2010
Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry
Susan R Foerster, Charles E Canter, Amy Cinar, et al.
Open Heart
|
November 28, 2017
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy
Jennifer E Ho, Ling Shi, Sharlene M Day, et al.
American Heart Journal
|
September 26, 2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
Ronald V Lacro, Harry C Dietz, Lisa M Wruck, et al.
JAMA Cardiology
|
February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study
Carolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Pediatrics
|
November 21, 2012
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Steven E Lipshultz, Tracie L Miller, Stuart R Lipsitz, et al.
Cardiology in the Young
|
November 21, 2022
A novel algorithm for classification of interatrial communications within the oval fossa in the newborn
Sofie Dannesbo, Elisabeth Blixenkrone-Moeller, Christian A Pihl, et al.
Circulation
|
October 2, 2013
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association
Steven E Lipshultz, M Jacob Adams, Steven D Colan, et al.
The Lancet. Oncology
|
September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
Steven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
Circulation
|
October 10, 2018
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
Carolyn Y Ho, Sharlene M Day, Euan A Ashley, et al.
Page
of 32
Search research articles
Search
Showing results (261-270 of 315) with videos related to
Sort By:
Page
of 32
Cardiology in the Young
|
February 12, 2011
Report from The International Society for Nomenclature of Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric cardiac disease (Part 1 - Procedural nomenclature)
Lisa Bergersen, Allen Dale Everett, Jorge Manuel Giroud, et al.
Circulation. Heart Failure
|
September 14, 2010
Ventricular remodeling and survival are more favorable for myocarditis than for idiopathic dilated cardiomyopathy in childhood: an outcomes study from the Pediatric Cardiomyopathy Registry
Susan R Foerster, Charles E Canter, Amy Cinar, et al.
Open Heart
|
November 28, 2017
Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy
Jennifer E Ho, Ling Shi, Sharlene M Day, et al.
American Heart Journal
|
September 26, 2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
Ronald V Lacro, Harry C Dietz, Lisa M Wruck, et al.
JAMA Cardiology
|
February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study
Carolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Pediatrics
|
November 21, 2012
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes
Steven E Lipshultz, Tracie L Miller, Stuart R Lipsitz, et al.
Cardiology in the Young
|
November 21, 2022
A novel algorithm for classification of interatrial communications within the oval fossa in the newborn
Sofie Dannesbo, Elisabeth Blixenkrone-Moeller, Christian A Pihl, et al.
Circulation
|
October 2, 2013
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association
Steven E Lipshultz, M Jacob Adams, Steven D Colan, et al.
The Lancet. Oncology
|
September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
Steven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
Circulation
|
October 10, 2018
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
Carolyn Y Ho, Sharlene M Day, Euan A Ashley, et al.
Page
of 32